Loxo Oncology (LOXO) Reports Q3 Loss of $2.26/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Loxo Oncology Reports Third Quarter 2018 Financial Results
November 8, 2018 6:45 AM ESTLarotrectinib New Drug Application (NDA) PDUFA date is November 26, 2018
LOXO-292 Registrational Data Expected in 2019
LOXO-292 NDA Submission Expected in Late 2019
Enrollment of First Patient in LOXO-305 Phase 1/2 Study on Track for Fourth Quarter 2018
STAMFORD, Conn., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq: LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers, today reported third quarter 2018 financial results.
In the third quarter we made significant progress across our pipeline, said Josh Bilenker, M.D., chief... More
